bioMérieux – First-Quarter 2025 Business Review

- **+12.7% organic sales growth in Q1 2025, fifth consecutive quarter with double-digit organic sales growth**
- **Strong momentum thanks to the four growth drivers of the GO•28 strategic plan growing +11.8% and the remarkable growth of BIOFIRE®[1] respiratory panels at +21% leveraging the strong respiratory season in Q1.**
- **Steady adoption of SPOTFIRE®[2] with 1,400 new instruments installed in the quarter and a 166% sales increase at €54m in the quarter.**
- **bioMérieux confirms the 2025 sales guidance for at least +7% growth at constant scope and exchange rates.**
- **In a highly volatile environment, bioMérieux remains confident in achieving at least 10% CEBIT[3] growth in 2025 versus 2024 at constant scope and exchange rates while closely monitoring the evolving tariff situation, assessing its financial impact and exploring mitigating actions.**
- **The currency effect[3] is now expected to have a negative impact of around - €35m to -€40m on the 2025 annual CEBIT versus around -€30m previously communicated.**

Pierre Boulud, Chief Executive Officer, said: "*With almost 13% sales growth in the first quarter of 2025, bioMérieux is starting the year strongly. In parallel, bioMérieux continued to launch innovative solutions addressing the needs of healthcare professionals and supporting our GO•28 strategic plan growth drivers: BIOFIRE® GI-Mid panel in the US, GENE-UP® Typer for food safety and quality customers, VITEK® COMPACT PRO in Microbiology and the SpinChip acquisition to strengthen our future presence in the Point of Care market segment. Despite the highly volatile and uncertain environment, bioMérieux remains confident in its capacity to achieve the 2025 guidance of at least +7% sales growth and at least +10% CEBIT growth both at constant scope and exchange rates.*"

Marcy l'Étoile (France), April 17th, 2025 – bioMérieux, a world leader in the field of *in vitro* diagnostics, today releases its business review for the three months ended March 31th, 2025.

SALES

Note: Unless otherwise stated, growth is expressed year-on-year at constant exchange rates and scope of consolidation (like-for-like).

Consolidated sales totaled €1,098 million in the first quarter of 2025, up 13.7% as reported from €965 million in first quarter of 2024. Organic growth (at constant exchange rates and scope of consolidation) stood at +12.7%, above expectations. Currency effect had a positive impact of €11 million over the first quarter sales,

[1] *In this press release BIOFIRE® refers to BIOFIRE® FILMARRAY® TORCH system and panels*
[2] *In this press release SPOTFIRE® refers to BIOFIRE® SPOTFIRE® system and panels*
[3] *As defined in Appendix#1*

PRESS RELEASE

due to the appreciation of the US dollar against the euro, slightly compensated by the depreciation of some Latin American currencies against euro.

Analysis of sales

In € millions

SALES – THREE MONTHS ENDED MARCH 31, 2024	**965**	
Currency effect	+11	1.1%
Changes in scope of consolidation	0	
Organic growth (at constant exchange rates and scope of consolidation)	+122	+12,7%
SALES – THREE MONTHS ENDED MARCH 31, 2025	**1,098**	**+13.7%**

ANALYSIS OF SALES BY APPLICATION

Sales by Application In € millions	**Q1 2025**	Q1 2024	% change as reported	**% change** at constant exchange rates and scope of consolidation
Clinical Applications	**937.8**	818.7	+14.5%	**+13.3%**
Molecular biology	**521.7**	409.6	+27.4%	**+24.7%**
BIOFIRE	**452.3**	374.8	+20.7%	**+18.1%**
SPOTFIRE	**54.3**	19.9	+172.0%	**+165.7%**
Other molecular	**15.2**	14.8	+2.7%	**+2.1%**
Microbiology	**326.1**	314.2	+3.8%	**+3.8%**
Immunoassays	**75.0**	83.3	-10.0%	**-9,4%**
Other lines(1)	**14.9**	11.6	+28.4%	**+33.8%**
Industrial Applications(2)	**160.1**	146.5	+9.3%	**+9.0%**
TOTAL SALES	**1,097.9**	965.2	+13.7%	**+12.7%**

(1) Including mainly BioFire Defense, R&D-related revenue arising on clinical applications
(2) Including R&D-related revenue arising on industrial applications.

- **Clinical applications** sales (85% of total sales), increased by 13% year-on-year to €938 million in the first quarter of 2025.
  - In **molecular biology**:
    - BIOFIRE® respiratory panels achieved a remarkable performance of +21%, illustrating the medical value of the solution in a context of a high respiratory season during the first quarter, especially in the US and in EMEA;
    - BIOFIRE® non-respiratory panels delivered a +11% sales increase in line with expectations, driven notably by EMEA, growing more than 15%;
    - The total BIOFIRE® installed base expanded by around +600 net units in Q1 2025, reaching 27,350 units;
    - The SPOTFIRE® installed base reached more than 4,400 instruments, a +45% increase over the quarter, with 1,400 new instruments installations, including an important one-off in Japan driven by a government funding scheme available until the end of Q1 2025. Total SPOTFIRE® sales reached €54m, a 166% increase versus the end of 2024.
  - In **microbiology**, the +4% increase in sales results from a combination of sales decrease in China driven by unfavorable healthcare spend trends, and a more than +7% increase in BACT/ALERT® and VITEK® ranges sales in other geographies.
  - In **immunoassays**, the sales were down -9%, negatively impacted by the global acceleration in the decline of the VIDAS® PCT sales and the Volume Base Procurement (VBP) scheme extension in China.

- **Industrial applications sales** (15% of total sales), grew 9% in Q1 2025 versus Q1 2024 led by strong demand for reagents in the Pharma Quality Control segment, especially in molecular, while Food Safety & Quality segment grew mid-single-digit.

ANALYSIS OF SALES BY REGION

Sales by Region In € millions	**Q1 2025**	Q1 2024	% change as reported	**% change** at constant exchange rates and scope of consolidation
North America	**543.7**	442.5	+22.9%	**+19.3%**
Latin America	**62.6**	59.9	+4.6%	**+14.0%**
EMEA(1)	**320.7**	303.4	+5.7%	**+5.9%**
Asia Pacific	**170.8**	159.4	+7.1%	**+6.7%**
TOTAL SALES	**1,097.9**	965.2	+13.7%	**+12.7%**

(1) Including Europe, the Middle East and Africa.

- In **North America** (49% of the consolidated total), revenue growth reached +19% versus Q1 2024, driven by close to 20% growth in BIOFIRE® reagents sales, the ramp up of SPOTFIRE®, and more than 9% growth in microbiology and Industrial Applications sales.

- In **Latin America** (6% of total sales), the region enjoyed a very solid growth of +14% organic and +8% without Argentina (high inflation country). Industrial Applications saw more than 20% sales growth, whilst each franchise of the Clinical Applications business witnessed double-digit increase in sales.

- Sales in the **Europe – Middle East – Africa** region (29% of the consolidated total) totaled €321 million in the first three months, up 6% year-on-year. BIOFIRE® sales were up +20% with strong growth in both RP and non-respiratory panels paired with Industry Applications reagent sales up +7% versus Q1 2024 while microbiology sales softened mainly on instruments.

- Sales in the **Asia Pacific** region (16% of the consolidated total) amounted to €171 million in the first quarter, growing +7% organically compared with same period of 2024, driven by +11% growth in Industrial Applications and a very strong quarter for SPOTFIRE® equipment sales in Japan while China (5% of total group sales) delivered a negative sales performance, impacted by downward pressure on local healthcare spend in hospitals.

2025 GUIDANCE

- bioMérieux confirms the 2025 sales guidance for at least +7% growth at constant scope and exchange rate.
- In a highly volatile environment, bioMérieux remains confident in achieving at least 10% CEBIT growth in 2025 versus 2024 at constant scope and exchange rates while closely monitoring the evolving tariff situation, assessing its financial impact and exploring mitigating actions.
- With 85% of its US sales products manufactured locally, bioMérieux is mainly exposed to US tariffs on the 15% of finished goods imported in the US and some imports of Chinese and European raw materials and components. Additionally, bioMérieux is exposed to China tariffs on imports from the US, with the China market accounting for approximately 5% of the group's sales.
- The currency effect is now expected to have a negative impact of around -€35m to -€40m on the 2025 annual CEBIT versus around -€30m previously communicated.

EVENTS OF FIRST QUARTER 2025

- **bioMérieux acquires Neoprospecta**

In January 2025, bioMérieux acquired Neoprospecta, a Brazil-based company that develops and markets innovative user-friendly data and genomics solutions for augmenting quality assurance programs and improve microbiological risk prevention in food and pharma industries.

- **bioMérieux strengthens its Point of Care presence with the acquisition of the immunoassay start-up SpinChip Diagnostics**

In January 2025, bioMérieux announced it has entered into an agreement to acquire SpinChip Diagnostics ASA, a privately held Norwegian diagnostics company that has developed a game-changing immunoassay diagnostics platform. The small benchtop analyzer is well adapted to near patient testing as it can deliver a result from a whole blood sample within ten minutes with the same high-sensitivity performance as the laboratory instruments.

- **bioMérieux receives U.S. FDA clearance for the new version of its molecular test targeting causes of gastroenteritis, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid**

In February 2025, bioMérieux announced that its BIOFIRE® FILMARRAY® Panel Mid has obtained clearance from the U.S. FDA. This midplex molecular panel tests for eleven of the most common bacteria, viruses and parasites associated with gastroenteritis, all from one sample, with results available in approximately 1 hour.

- **bioMérieux launches GENE-UP® TYPER, an innovative diagnostic solution for food industries to rapidly analyze the root cause of contamination of Listeria monocytogenes.**

In February 2025, bioMérieux announced the launch of GENE-UP® TYPER, a real-time PCR diagnostic solution comprising a test and a web application, for the rapid characterization of microorganism strains. The first version, GENE-UP® TYPER LMO, targets Listeria monocytogenes. The solution allows for the rapid identification of the source of contamination and accelerates the decision-making process to minimize or even prevent further contaminations in the future. This automated system brings high-tech solutions to the pathogen detection market with its speed, ease of use, and precision.

- **FDA 510(k) Clearance for VITEK® COMPACT PRO, a new ID/AST system to fight against antimicrobial resistance**

In March 2025, bioMérieux received FDA 510(k) Clearance for its VITEK COMPACT PRO. This innovative system for microorganism identification (ID) and antibiotic susceptibility testing (AST) will benefit clinical laboratories to help diagnose infectious diseases and combat antimicrobial resistance, and industrial laboratories to identify contaminants for ensuring consumer safety. VITEK® COMPACT PRO combines the latest diagnostic technology with the globally acknowledged advantages of its predecessor: VITEK® 2 COMPACT.

SUBSEQUENT EVENTS

- **bioMérieux obtains CE-marking for LUMED™ APSS™, a cutting-edge software solution to aid medical decision-making in Antimicrobial Stewardship**

In April 2025, bioMérieux received CE marking for LUMED™ APSS™, an advanced clinical decision support system (CDSS) designed to enhance antimicrobial stewardship programs (ASP) and improve patient outcomes. LUMED™ APSS™ is a software solution designed for infectious disease (ID) pharmacists and physicians as an aid to address the challenges of antimicrobial overuse and misuse, which contribute to the rise of drug-resistant organisms. The system's multi-step process helps ensure antimicrobial treatments are continuously evaluated and adjusted based on the latest clinical data, promoting the de-escalation of unnecessary treatments and the use of oral alternatives when appropriate.

- **Decision of the Lyon Commercial Court in a case between bioMérieux S.A. and Qiagen GmbH and Qiagen N.V.**

By an interim order dated April 11, 2025, it was held that the press release published on March 3, 2025 on the Qiagen GmbH website constitutes an act of disparagement and unfair competition by Qiagen GmbH and Qiagen N.V. against bioMérieux. The full decision (together with an unofficial English translation) will be available on the bioMérieux website (www.biomerieux.com) for the coming three months. Although it may still be appealed, this decision is provisionally enforceable.

INVESTOR PRESENTATION

bioMérieux will hold an investor presentation on Thursday, April 17, 2025 at 2:00 pm Paris time (GMT+1). The presentation will be given in English and will be accessible via webcast under following link:

https://event.webcasts.com/starthere.jsp?ei=1714513&tp_key=982e52e421

If you are unable to join the webcast URL, please join audio conference with:.

France	Europe	United States
+33 (0)1 70 72 25 50	+44 (0)330 165 3655	+1 323-701-0225
Access code: **2797113**		

INVESTOR CALENDAR

Annual General Meeting	May 15, 2025
Second-quarter 2025 sales and first-half 2025 results	September 4, 2025
Third-quarter 2025 sales	November 4, 2025

ABOUT BIOMÉRIEUX

Pioneering Diagnostics

A world leader in the field of *in vitro* diagnostics for 60 years, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2024, revenues reached €4.0 billion, with over 93% of sales outside of France.

bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the Euronext Paris stock market.
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP
Corporate website: www.biomerieux.com. Investor website:

CONTACTS

Investor Relations

bioMérieux
Aymeric Fichet
Tel.: +33 (0)4 78 87 20 00
investor.relations@biomerieux.com

Media Relations

bioMérieux
Romain Duchez
Tel.: +33 (0)4 78 87 21 99
media@biomerieux.com

France
Laurence Heilbronn (Image 7)
Tel.: +33 (0)1 53 70 74 48
lheilbronn@image7.fr

United States
Liza Deckelbaum (Seez)
Tel.: (919) 521-0507
lizad@seeztoday.com

PRESS RELEASE

APPENDIX 1: GLOSSARY & DISCLAIMER

DEFINITIONS

Changes in the scope of consolidation:
The effects of changes in the scope of consolidation are determined:

- for acquisitions for the period, by deducting from sales and operating expenses for the period the amount of sales and operating expenses made during the period by the entities acquired from their entry into the scope of consolidation;
- for acquisitions of the previous period, by deducting from sales and operating expenses for the period the amount of sales and operating expenses made during the months in which the acquired entities were not consolidated during the previous period;
- for disposals for the period by adding to sales and operating expenses for the period the amount of sales and operating expenses made by the entities sold the previous period, during the months in which these entities are no longer consolidated over the current period;
- for disposals for the previous period, by adding to the sales and operating expenses of the period the sales and operating expenses made during the preceding period by the entities sold.

Contributive operating income before non-recurring items (CEBIT): operating income before non-recurring items, excluding items relating to the amortization and impairment of intangible assets related to acquisitions and acquisition-related costs. The Company considers that this indicator provides the best possible representation of the operational performance of the Company.

Currency effect: established by comparing the actual numbers converted at the average exchange rates of the current year to the actual numbers converted at the average exchange rates of the comparative period. In practice, those rates are either average rates communicated by the ECB, or hedged rates if hedging instruments have been set up.

Operating income before non-recurring items: recurring income less recurring expenses and amortization and impairment of intangible assets related to acquisitions and acquisition-related costs. Non-recurring expenses and income are not included.

DISCLAIMER

The forward-looking statements contained in this document are based, entirely or partially, on assessments or judgments that may change or be modified, due to uncertainties and risks related to the Company's economic, financial, regulatory and competitive environment, notably those described in the 2024 Universal Registration Document. Accordingly, the Company cannot give any assurance nor make any representation as to whether the objectives will be met. The Company does not undertake to update or otherwise revise any forecasts or objectives presented herein, except in compliance with the disclosure obligations applicable to companies whose shares are listed on a stock exchange.